← All trials
NCT00453271
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2007
- Primary completion
- Oct 1, 2008
- Completion date
- Oct 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 443
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- BlueWillow BiologicsLead sponsor
- InnovadermOverall official - principal investigator
- Virginia Clinical Research, Inc.Overall official - principal investigator
- The Guenther Dermatology Research CentreOverall official - principal investigator
- Minnesota Clinical Study CenterOverall official - principal investigator
- Oregon Dermatology and Research CenterOverall official - principal investigator
- EntraLogix Clinical Group Inc.Overall official - principal investigator
- K. Papp Clinical ResearchOverall official - principal investigator
- Derm Research IncorporatedOverall official - principal investigator
- Northwest Clinical TrialsOverall official - principal investigator
- Endeavor Clinical TrialsOverall official - principal investigator
- International Dermatology Research Inc.Overall official - principal investigator
- Lynderm Research IncOverall official - principal investigator
- Dermatology Research Center, IncOverall official - principal investigator
- Eastern Canada Cutaneous Research Associates Ltd.Overall official - principal investigator
- J&S Studies Inc.Overall official - principal investigator
- UltraNova SkincareOverall official - principal investigator
- Oregon Medical Research CenterOverall official - principal investigator
- Centre de Recherche Dermatologique du Quebec MetropolitaineOverall official - principal investigator
- NewLab Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.